Hyderabad Bharat Biotech International and Global Biopharma Major GSK announced cooperation in the development of his candidate for Shigella Altsonflex1-2-3.
Based on their consent, Bharat Biotech will lead the further development of Altsonflex1-2-3, including clinical studies of phase 3, regulatory progress and extensive production. GSK companies continued to support the program by helping with the proposal of clinical evaluation, providing external financing and contributing to access and commercial strategy and commercial strategy.
Shigellosis is an acute human inflammatory disease of the colon caused by a gram -negative shigella. It is characterized by watery diarrhea, fever, abdominal convulsions and pain and bloody and mucus filled with stools. There is currently no licensed Shigella vaccine.
Now the Phase 3 tests are Altsonflex1-2-3 ready to become the first scalable, affordable and worldwide vaccine for the fight against this urgent threat of public health, Bharat Biotech said with a license candidate.
GSK candidate excels in the wide coverage of serotype, innovative generalized modules for platform based on membrane antigens (GMMA) and robust early clinical results. It has shown a strong profile of security and immunogenicity in both European and African experiments, even in the primary target population of 9 months of infants, she said.
Study of Phase 1 in Europe has shown a favorable safety profile and a strong immune response. The following Study of Phase 2 in Africa, including vaccination of nine -month -old infants, primary target populations, did not report any security concerns. The temporary results of 2024 confirmed that the candidate has met its preset immunogenic goals.
“This cooperation (Shigella vaccine) combines our strengths in the field of innovation, production and global health commitment. The use of GMMA technology reflects our mission to provide accessible vaccines that protect and improve lives worldwide,” said Bharat Biotech Krishna.
GMMA technology uses bacterial external membranes to supply antigen to the immune system. This approach allows high -profile production with a simple and cost -effective production process and offers a way to create available population vaccines for insufficiently operated, the company said.
The Global Health Referent GSK Thomas Breuer said that “this agreement allows us to combine our strengths in science, research and technology with the ability to develop and supply vaccines on scale, potentially prevents illness and save lives around the world”.
Cooperation builds on the current relationship of GSK with Bharat Biotech, after the transfer of products and a license agreement in 2021 for the first vaccine against malaria in the world, RTS, p.
Published – June 12, 2025 17:00
